<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1705222032
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        URSOFALK 250MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        URSODEOXYCHOLIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        103.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LOSAN PHARMA GMBH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LOSAN PHARMA GMBH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DR. FALK PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A05AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ursodeoxycholic acid, the active substance in Ursofalk<sup>&reg;</sup> 250 mg capsules, is a naturally-occurring bile acid. Only small amounts are found in human bile.</p><p>&nbsp;</p><p>&nbsp;</p><p>Ursofalk<sup>&reg;</sup> 250 mg capsules are used:</p><p><u>&nbsp;</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to dissolve cholesterol gallstones. These stones must not show as shadows on X-ray and should not exceed 15 mm in diameter. The gall bladder must still be working despite the gallstone(s).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat inflammation of the stomach lining caused by the reflux of bile acids (bile reflux gastritis)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the treatment of primary biliary cirrhosis (PBC, a chronic disease of the bile ducts, up to cirrhosis of the liver), in patients without decompensated liver cirrhosis (diffuse chronic disease of the liver, at a stage when the disease-related reduction in liver function can no longer be compensated for).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the treatment of liver disease associated with cystic fibrosis (also called mucoviscidosis) in children aged 6 years to less than 18 years</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT take Ursofalk<sup>&reg;</sup> 250 mg capsules if</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are hypersensitive (allergic) to bile acids (such as ursodeoxycholic acid) or to any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an acute inflammation of the gall bladder or biliary tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an obstruction of the biliary tract (blockage of the common bile duct or cystic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; duct)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you suffer from frequent cramp-like pains in the upper abdomen (biliary colic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor has told you that you have calcified gallstones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your gall bladder is not able to contract properly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your child has a blockage of the bile ducts and has reduced bile flow (biliary atresia), even after surgery.</p><p>&nbsp;</p><p>Please ask your doctor about any of the conditions mentioned above. You should also ask if you have previously had any of these conditions.</p><p>&nbsp;</p><p>Warnings and precautions:</p><p>Ursofalk<sup>&reg;</sup> 250 mg capsules must be used under medical supervision.</p><p>&nbsp;</p><p>Your doctor should test your liver function regularly every 4 weeks for the first 3 months of treatment. After this time, it should be monitored at 3-month intervals.</p><p>&nbsp;</p><p>When used to dissolve gallstones, your doctor should arrange for a scan of your gall bladder after the first 6-10 months of treatment.</p><p>&nbsp;</p><p>If you are a woman and take this medicine for dissolution of gallstones you should use an effective non-hormonal method of contraception, since hormonal contraceptives may encourage the formation of gallstones.</p><p>&nbsp;</p><p>When used in the treatment of PBC, in rare cases the symptoms (e.g. itching) may worsen at the beginning of treatment. If this happens, please speak to your doctor about reducing your initial dose.</p><p>&nbsp;</p><p>Tell your doctor immediately if you are suffering from diarrhoea, as you may need the dose to be reduced or to stop taking Ursofalk<sup>&reg;</sup> 250 mg capsules.</p><p><em>&nbsp;</em></p><p>Other medicines and Ursofalk<sup>&reg;</sup> 250 mg capsules</p><p>&nbsp;</p><p>Please tell your doctor if you are taking/using, have recently taken/used or might take/use any other medicines which contain the following active substances. The effects of these medicines may be altered (interactions):</p><p>&nbsp;</p><p>A reduction in the effects of the following medicines is possible when taking Ursofalk<sup>&reg;</sup> 250 mg capsules:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colestyramine, colestipol (medicines to lower blood lipids) or aluminium hydroxide, smectite (aluminium oxide)-containing antacids (agents that bind gastric acid). If you are taking medication that contains any of these active substances, it must be taken at least two hours before or after Ursofalk<sup>&reg;</sup> 250 mg capsules.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciprofloxacin, dapsone (antibiotics), nitrendipine (a medicine used to treat high blood pressure) and other medicines which are metabolised in a similar way. Your doctor may possibly alter the dose of these medicinal products.</p><p>&nbsp;</p><p>A change in the effects of the following medicines is possible when taking Ursofalk<sup>&reg;</sup> 250 mg capsules:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (a medicine that inhibits the immune system). If you are being treated with ciclosporin, your doctor should check the amount of ciclosporin in your blood. Your doctor will adjust its dose, if necessary.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rosuvastatin (a medicine for high blood cholesterol)</p><p>&nbsp;</p><p>If you are taking Ursofalk<sup>&reg;</sup> 250 mg capsules to dissolve gallstones, please tell your doctor if you are also taking oestrogen-containing medicinal products (such as &rdquo;the Pill&rdquo;) or certain medicines to lower your cholesterol levels that contain clofibrate, for example. These medicines may encourage the formation of gallstones and counteract the effects of Ursofalk<sup>&reg;</sup> 250 mg capsules in dissolving the gallstones.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking or using, or have recently taken or used or might take/use any other medicines.</p><p><u>&nbsp;</u></p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Fertility:</p><p>Animal studies did not show any influence of this medicine on fertility.</p><p>There are no data available showing the effect of this medicine on human fertility.</p><p>&nbsp;</p><p>Pregnancy:</p><p>There are no or limited amounts of data from the use of ursodeoxycholic acid in pregnant women. Studies in animals have shown that the growth and development of the baby may be affected. You should not take Ursofalk<sup>&reg;</sup> 250 mg capsules during pregnancy unless your doctor thinks it is absolutely necessary.</p><p>&nbsp;</p><p>Women of child-bearing potential:</p><p>Even if you are not pregnant, you should discuss this possibility with your doctor as women of child-bearing age should only be treated if they are using a reliable method of contraception. Non-hormonal methods of contraception or low-dose oestrogen contraceptives (&rdquo;the Pill&rdquo;) are recommended. You should use an effective non-hormonal method of contraception if you are taking Ursofalk<sup>&reg;</sup> 250 mg capsules to dissolve gallstones, as hormonal contraceptives may encourage the formation of gallstones.</p><p>&nbsp;</p><p>Your doctor will check that you are not pregnant before starting the treatment.</p><p>Breast-feeding:</p><p>There are only a few documented cases of ursodeoxycholic acid use in breast-feeding women. Levels of ursodeoxycholic acid in milk are very low and probably no adverse reactions will occur in breastfed infants.</p><p>&nbsp;</p><p>Children:</p><p>There are no age limits to the use of Ursofalk<sup>&reg;</sup> 250 mg capsules. The administration of Ursofalk<sup>&reg;</sup> 250 mg capsules is based on body weight and the medical condition. For children who are not able to swallow capsules or weigh less than 47 kg, Ursofalk<sup>&reg;</sup> is available in a liquid form (Ursofalk<sup>&reg;</sup> 250mg/5ml suspension).</p><p><u>&nbsp;</u></p><p>Driving and using machines:</p><p>Ursofalk<sup>&reg;</sup> 250 mg capsules have no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><u>&nbsp;</u></p><p>To dissolve cholesterol gallstones</p><p>&nbsp;</p><p>Dosage</p><p>Approx. 10 mg ursodeoxycholic acid per kg body weight (BW) daily, as follows:</p><p>&nbsp;</p><p>up to 60 &nbsp; kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 capsules</p><p>61 &ndash; 80 &nbsp;&nbsp;&nbsp; kg&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 capsules</p><p>81 &ndash; 100 &nbsp; kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 capsules</p><p>over 100 kg&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 capsules</p><p>&nbsp;</p><p>How to take Ursofalk<sup>&reg;</sup> 250 mg capsules</p><p>Swallow the capsules whole with some liquid. Take the capsules in the evening at bedtime. Take the Ursofalk<sup>&reg;</sup> 250 mg capsules regularly.</p><p>&nbsp;</p><p>&nbsp;</p><p>Duration of treatment</p><p>It generally takes 6-24 months to dissolve gallstones. If there is no reduction in the size of the gallstones after 12 months, therapy should be stopped.</p><p>Every 6 months, your doctor should check whether the treatment is working. At each of these follow-up examinations, it should be checked whether calcification of the gallstones has occurred since the last time. If this is the case, your doctor will stop the treatment.</p><p>To treat bile reflux gastritis</p><p>&nbsp;</p><p>Dosage and how to take Ursofalk<sup>&reg;</sup> 250 mg capsules</p><p>Take one capsule of Ursofalk<sup>&reg;</sup> 250 mg capsules in the evening at bedtime; swallow the capsule whole with some liquid.</p><p>&nbsp;</p><p>Duration of treatment</p><p>Ursofalk<sup>&reg;</sup> 250 mg capsules are usually taken for 10-14 days in the treatment of bile reflux gastritis. Your doctor will decide how long you have to take the capsules, depending on the course of your medical condition.</p><p>&nbsp;</p><p>&nbsp;</p><p>Treatment of primary biliary cirrhosis (chronic inflammatory disease of the bile ducts)</p><p><em>&nbsp;</em></p><p>Dosage</p><p>During the first 3 months of treatment, you should take Ursofalk<sup>&reg;</sup> 250 mg capsules in the morning, at midday, and in the evening. As liver function tests improve, the total daily dose may be taken once a day in the evening.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Body weight<br />BW (kg)</p></td><td colspan="4" style="vertical-align:top"><p>Ursofalk<sup>&reg;</sup> 250 mg capsules</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>First 3 months</p></td><td style="vertical-align:top"><p>Subsequently</p></td></tr><tr><td style="vertical-align:top"><p>Morning</p></td><td style="vertical-align:top"><p>Midday</p></td><td style="vertical-align:top"><p>Evening</p></td><td style="vertical-align:top"><p>Evening</p><p>(once daily)</p></td></tr><tr><td style="vertical-align:top"><p>47 &ndash; 62</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>63 &ndash; 78</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>79 &ndash; 93</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>94 &ndash; 109</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>over 110</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>7</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Ursofalk<sup>&reg;</sup> 250mg/5ml suspension is available if you weigh less than 47 kg or cannot swallow Ursofalk<sup>&reg;</sup> 250 mg capsules.</p><p>&nbsp;</p><p>How to take Ursofalk<sup>&reg;</sup> 250 mg capsules</p><p>Swallow the capsules whole, not chewed, with some liquid. Take the Ursofalk<sup>&reg;</sup> 250 mg capsules regularly.</p><p><em><u>&nbsp;</u></em></p><p>Duration of treatment</p><p>Intake of Ursofalk<sup>&reg;</sup> 250 mg capsules can be continued indefinitely in cases of primary biliary cirrhosis.</p><p>&nbsp;</p><p>Note:</p><p>In patients with primary biliary cirrhosis, the symptoms of your illness, such as itching, may worsen at the start of treatment. This only occurs in rare cases. In this case, therapy can be continued with a lower daily dose of Ursofalk<sup>&reg;</sup> 250 mg capsules. Your doctor will then gradually increase the daily dose, week by week, until you reach the required dose.</p><p>&nbsp;</p><p><strong>Use in children (6 years to less than 18 years) for treatment of a liver disease associated with cystic fibrosis</strong></p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The recommended daily dose is 20 mg per kg body weight, divided in 2-3 doses. Your doctor may want to increase the dose further to 30 mg per kg body weight daily if necessary.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Body weight</p><p>BW [kg]</p></td><td rowspan="2"><p>Daily dose</p><p>(mg/kg BW)</p></td><td colspan="3"><p>&nbsp;</p><p>Ursofalk<sup>&reg;</sup> 250 mg capsules</p></td></tr><tr><td><p>Morning</p></td><td><p>Midday</p></td><td><p>Evening</p></td></tr><tr><td><p>20 &ndash; 29</p></td><td><p>17-25</p></td><td><p>1</p></td><td><p>&nbsp;--</p></td><td><p>1</p></td></tr><tr><td><p>30 &ndash; 39</p></td><td><p>19-25</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>40 &ndash; 49</p></td><td><p>20-25</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p>50 &ndash; 59</p></td><td><p>21-25</p></td><td><p>1</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p>60 &ndash; 69</p></td><td><p>22-25</p></td><td><p>2</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p>70 &ndash; 79</p></td><td><p>22-25</p></td><td><p>2</p></td><td><p>2</p></td><td><p>3</p></td></tr><tr><td><p>80 &ndash; 89</p></td><td><p>22-25</p></td><td><p>2</p></td><td><p>3</p></td><td><p>3</p></td></tr><tr><td><p>90 &ndash; 99</p></td><td><p>23-25</p></td><td><p>3</p></td><td><p>3</p></td><td><p>3</p></td></tr><tr><td><p>100 &ndash; 109</p></td><td><p>23-25</p></td><td><p>3</p></td><td><p>3</p></td><td><p>4</p></td></tr><tr><td><p>&gt;110</p></td><td><p>&nbsp;</p></td><td><p>3</p></td><td><p>4</p></td><td><p>4</p></td></tr></tbody></table><p>&nbsp;</p><p>If you feel that the effect of Ursofalk<sup>&reg;</sup> 250 mg capsules is too strong or too weak, please talk to your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p>If you take more Ursofalk<sup>&reg;</sup> 250 mg capsules than you should:</p><p>Diarrhoea may occur as a result of overdose. Please inform your doctor immediately if you have persistent diarrhoea. If you do suffer from diarrhoea, make sure you drink enough liquids to restore your fluid and electrolyte balance.</p><p>&nbsp;</p><p>If you forget to take your Ursofalk<sup>&reg;</sup> 250 mg capsules:</p><p>Do not take more capsules the next time, but just continue the treatment with the prescribed dose.</p><p>&nbsp;</p><p>If you stop taking Ursofalk<sup>&reg;</sup> 250 mg capsules:</p><p>Always speak to your doctor before you interrupt treatment with Ursofalk<sup>&reg;</sup> 250 mg capsules or stop your treatment early.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;</p><p>Common side effects (occurring in less than 1 in 10 but more than 1 in 100 people treated):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; soft, loose stools or diarrhoea</p><p>Very rare side effects (occurring in less than 1 in 10,000 people treated):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during the treatment of primary biliary cirrhosis: severe right-sided upper abdominal pain, severe worsening (decompensation) of liver cirrhosis which partially regresses after treatment is discontinued</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcification of gallstones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nettle rash (urticaria)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Keep below 25&deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Ursofalk<sup>&reg;</sup> 250 mg capsules contain</p><p>&nbsp;</p><p>The active substance is ursodeoxycholic acid. One capsule contains 250 mg ursodeoxycholic acid.</p><p>The other ingredients are</p><p>gelatin, colloidal silica anhydrous, magnesium stearate (Ph.Eur.), maize starch, sodium dodecyl sulfate, titanium dioxide and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ursofalk® 250 mg capsules are white and opaque. They contain a white powder or granules.

Ursofalk® 250 mg capsules are available in packs of 50 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DR. FALK PHARMA GmbH</p><p>Leinenweberstr. 5</p><p>79108 Freiburg</p><p>Germany</p><p>Tel: (0761) 1514 0</p><p>Fax: (0761) 1514 321</p><p>Email: zentrale@drfalkpharma.de</p><p>&nbsp;</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p>&nbsp;</p><p>Cigalah Group</p><p>Office 511, 5th floor, Aqaria Building 2,</p><p>Olaya St, Riyadh 11533, Saudi Arabia.</p><p>P.O. Box 50622</p><p>Tel: +966 11 4191471</p><p>Fax: +966 11 4191652</p><p>Email: info.reg@cigalah.com.sa</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>- <em>Saudi Arabia:</em></p><p>National Pharmacovigilance and Drug Safety Center (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>- <em>Other GCC States:</em></p><p>o&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>This is a Medicament</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p><p>&nbsp;</p><p>&nbsp;</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p><p>This patient information leaflet is approved by the Saudi Food and Drug Authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in August 2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">حمض أورسوديوكسيكوليك هو المادة الفعالة في كبسولات Ursofalk&reg; (يرسوفالك)250 مليجرام، وهو حمض صفراوي موجود بصورة طبيعية،وتوجد كميات صغيرة في العصارة الصفراوية فقط للإنسان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تُستعمل كبسولاتUrsofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام في:</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفتيت حصوات المرارة والحفاظ على مستوى الكوليسترول.&nbsp; يجب عدم ظهور هذه الحصوات كظلال على الأشعة السينية، كما ينبغي عدم تجاوز قطرها15ملم، ويجب أن تظل المرارة تعمل على الرغم من وجود حصوة أو حصوات بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التهاب بطانة المعدة الناتج عن ارتداد الأحماض الصفراوية(الالتهاب الناتج عن ارتداد الحمض الصفراوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج تليف الكبد الصفراوي الأولي (مرض مزمن في القناة الصفراوية يصل إلى تليف الكبد) في المرضى الذين لم يتم تعويضهم عن تليف الكبد (انتشار مرض مزمن في الكبد للمرحلة التي لم يعد من الممكن تعويض انخفاض وظائف الكبد المتعلقة بالأمراض ذات الصلة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أمراض الكبد المرتبطة بالتليف الكيسي (تسمى أيضا تلزج المخاط) في الأطفال الذين تتراوح أعمارهم بين6 سنوات إلى أقل من 18عامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عدم تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام إذا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك حساسية شديدة (مفرطة) للحمض الصفراوي (مثل حمض أورسوديوكسيكوليك)أو أي من المكونات الأخرى الموجودة في هذا العقار (المدرجة في القسم السادس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك التهاب حاد في المرارة أو القناة الصفراوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك انسداد في القنوات الصفراوية (انسداد في القناة الصفراوية أو القناة المرارية المشتركة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من آلام متكررة مثل تقلص متكرر في الجزء العلوي من البطن (المغص المراري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبرك الطبيب بأن لديك حصوات متكلسة في المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت المرارة غير قادرة على الانقباض بشكل صحيح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان طفلك يعاني من انسداد في القناة الصفراوية، ولديه انخفاض في تدفق الصفراء (رتق القناة الصفراوية)، حتى بعد إجراء عملية جراحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى سؤال طبيبك حول أي من الحالات المذكورة أعلاه،يجب عليك أن تسأل أيضًا في حال تعرضك لأي من هذه الحالات في الماضي.</p><p dir="RTL">&nbsp;</p><p>التحذيرات والاحتياطات:</p><p dir="RTL">يجب استعمال كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام تحت الإشراف الطبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يقوم طبيبك باختبار وظائف الكبد بشكل دوري كل4 أسابيع في الثلاثة أشهر الأولى من بدء العلاج،بعد ذلك ينبغي القيام بالاختبار كل ثلاثة أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما استعمال العقار لتفتيت حصوات المرارة، يجب أن يتخذ طبيبك الترتيبات اللازمة لفحص المرارة بعد مدة تتراوح بين 6 &nbsp;إلى 10 &nbsp;أشهر من بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة تناول هذا العقار من قبل الإناث لتفتيت حصوات المرارة،يجب عليهن استعمال وسيلة غير هرمونية فعالة لمنع الحمل لأن وسائل منع الحمل الهرمونية قد تشجع على تكوين حصوات المرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما استعمال هذا العقار في علاج تليف الكبد الصفراوي الأولي، في حالات نادرة قد تزداد بعض الأعراض (مثل الحكة) سوءًا في بداية العلاج،في حالة حدوث ذلك، يرجى التحدث مع طبيبك حول خفض الجرعة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك فورًا إذا كنت تعاني من الإسهال، حيث قد تحتاج إلى خفض الجرعة أو التوقف عن تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام.</p><p dir="RTL"><em>&nbsp;</em></p><p>كيفية تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام مع أدوية أخرى</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إخبار الطبيب إذا كنت تتناول أو تستعمل حاليًا أي أدوية أخرى قد تحتوي على المواد الفعالة التالية أو سبق استعمالك أو تناولك لها في الآونة الأخيرة أو قد تتناولها أو تستعملها في المستقبل،حيث قد يتم تغيير آثار هذه الأدوية (التفاعلات):</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن حدوث انخفاض في آثار الأدوية التالية عند تناولها مع كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولسترامين أو كوليستيبول (أدوية لخفض نسبة الدهون في الدم) أو هيدروكسيد الألومنيوم أو سمكتيت (أكسيد الألومنيوم) التي تحتوي على مضادات الحموضة (العوامل التي تتحكم في حمض المعدة)، إذا كنت تتناول عقار يحتوي على أي من هذه المواد الفعالة، يجب أن يؤخذ قبل ساعتين على الأقل من تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك)250 مليجرام أو بعدها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيبروفلوكساسين، دابسون (مضادات حيوية)، &nbsp;<em>نيترينديبين</em> (عقار يستخدم لعلاج ارتفاع ضغط الدم) وغيرها من الأدوية التي يتم تمثيلها بطريقة مماثلة، حيث قد يقوم طبيبك بتغيير الجرعة لتناول هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن حدوث تغير في آثار الأدوية التالية عند تناولها مع كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (عقار مثبط للجهاز المناعي)، إذا كنت تُعالج بسيكلوسبورين، ينبغي على الطبيب التحقق من كمية سيكلوسبورين في دمك،قد يقوم طبيبك بتعديل الجرعة إذا لزم الأمر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رسيوفاستاتين (عقار لارتفاع مستوى الكوليسترول في الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام لتفتتت حصوات المرارة، يرجى إخبار الطبيب إذا كنت تتناول أيضًا بعض الأدوية الطبية المحتوية على هرمون الاستروجين (مثل &quot;حبوب منع الحمل&quot;) أو بعض الأدوية لخفض مستويات الكولسترول والتي تحتوي على كلوفيبرات، على سبيل المثال،يمكن لهذه الأدوية أن تشجع على تكوين حصوات المرارة وإبطال آثار كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام في تفتيت حصوات المرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول حاليًا أدوية أخرى أو تناولتها مؤخراً أو قد تتناولها في المستقبل.</p><p dir="RTL"><u>&nbsp;</u></p><p>الحمل والرضاعة الطبيعية والخصوبة</p><p dir="RTL">استشيري طبيبك أو الصيدلي إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية أو تعتقدين أنك قد تكوني حاملاً أو تخططين لإنجاب طفل قبل تناول هذا العقار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخصوبة:</p><p dir="RTL">لم تُظهر الدراسات التي أُجريت على الحيوانات أي تأثير لهذا العقار على الخصوبة.</p><p dir="RTL">لا توجد بيانات متاحة تُظهر تأثير هذا العقار على خصوبة الإنسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل:</p><p dir="RTL">لا توجد بيانات فيما يتعلق باستخدام حمض أورسوديوكسيكوليك في النساء الحوامل أو توجد نسبة قليلة منها،ولكن قد أظهرت الدراسات التي أُجريت على الحيوانات بعض التأثر على نمو صغارها وتطورهم،لذا يجب عدم تناول كبسولات Ursofalk&reg; (يرسوفالك) 250 مليجرام أثناء الحمل ما لم يقرر الطبيب أن ذلك من حالات الضرورة القصوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">النساء في وضع الإنجاب المحتمل:</p><p dir="RTL">حتى إذا لم تكوني حاملاً، يجب عليك مناقشة هذا الاحتمال مع طبيبك كامرأة في سن الإنجاب إذا كان لديه طريقة يمكن الاعتماد عليها لمنع الحمل،يُنصح باتباع أساليب غير هرمونية لمنع الحمل أو تناول جرعة منخفضة من الاستروجين كوسائل لمنع الحمل (&quot;حبوب منع الحمل&quot;)،كما يجب عليكِ استخدام وسيلة غير هرمونية فعالة لمنع الحمل إذا كنت تتناولين كبسولات Ursofalk&reg; (يرسوفالك)250 مليجرام لتفتيت حصوات المرارة، حيث قد تشجع وسائل منع الحمل الهرمونية على تكوين حصوات المرارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يتحقق طبيبك من أنك لست حاملا قبل البدء في العلاج.</p><p dir="RTL">الرضاعة:</p><p dir="RTL">لا يوجد سوى عدد قليل من الحالات الموثقة لاستخدام حمض أورسوديوكسيكوليك في النساء المرضعات،حيث تنخفض للغاية مستويات حمض أورسوديوكسيكوليك في اللبن، وربما لا تحدث ردود فعل سلبية في الرضع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>&nbsp;</u></p><p>الأطفال:</p><p dir="RTL">لا توجد حدود للسن لاستخدام كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام،يعتمد استعمال كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام على وزن الجسم والحالة الصحية،بالنسبة للأطفال الذين يتعذر عليهم ابتلاع الكبسولات أو يقل وزنهم عن 47 كيلوجرام، تتوافر كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام في شكل سائل (معلق Ursofalk<sup>&reg;</sup>&quot;يرسوفالك&quot; 250 مليجرام/5مليلتر).</p><p dir="RTL"><u>&nbsp;</u></p><p>القيادة واستخدام الآلات:</p><p dir="RTL">لا يوجد لكبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام أي تأثير يُذكر فيما يتعلق بالقدرة على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص على تناول العقار وفق إرشادات الطبيب،وتحقق من طريقة تناوله من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><u>&nbsp;</u></p><p>تفتيت حصوات المرارة والحفاظ على مستوى الكوليسترول</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة</p><p dir="RTL">حوالي10 مليجرام من حمض الأورسوديوكسيكوليك لكل كيلوجرام من وزن الجسم يوميًا على النحو التالي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">حتى وزن 60 كجم&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp; كبسولتان</p><p dir="RTL">من61إلى 80 كجم&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 3 كبسولات</p><p dir="RTL">من 81 إلى 100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كجم &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 كبسولات</p><p dir="RTL">أكثر من 100 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كجم &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5كبسولات</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيفية تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام</p><p dir="RTL">يتم ابتلاع الكبسولات كاملة مع بعض السوائل.يرجى تناول الكبسولات مساءً وقت النوم. قم بتناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام بصفة منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج</p><p dir="RTL">يستغرق العقار عادة مدة تتراوح بين 6 إلى 24 شهرًا لتفتيت حصوات المرارة،ولكن في حالة عدم وجود أي انخفاض في حجم حصوات المرارة بعد 12 شهرًا، يجب أن يتوقف العلاج.</p><p dir="RTL">يجب أن يتحقق الطبيب كل 6 أشهر من فعالية العلاج،في كل من مرات المتابعة هذه، يجب التحقق من وقت حدوث تكلس لحصوات المرارة منذ آخر مرة،في هذه الحالة،سوف يقوم طبيبك بإيقاف هذا العقار.</p><p>التهاب المعدة الناتج عن ارتداد الأحماض الصفراوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة وكيفية تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام</p><p dir="RTL">تناول كبسولة واحدة من كبسولات Ursofalk<sup>&reg;</sup><sup> </sup>(يرسوفالك) 250 مليجرام مساءً عند وقت النوم،وقم بابتلاع الكبسولة كاملة مع بعض السوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج</p><p dir="RTL">يتم تناول كبسولات Ursofalk<sup>&reg;</sup><sup> </sup>(يرسوفالك) 250 مليجرام لمدة تتراوح عادة بين 10 إلى 14 يوم عند علاج التهاب المعدة الناتج عن ارتداد العصارة الصفراوية،سوف يقرر طبيبك مدة تناول الكبسولات والذي يتوقف على مسار حالتك الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>علاج تليف الكبد الصفراوي الأولي (مرض التهاب مزمن في القناة الصفراوية)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">الجرعة</p><p dir="RTL">خلال الثلاثة أشهر الأولى من العلاج، يجب أن تؤخذ كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام في الصباح، عند الظهيرة، وفي المساء، مع تحسن اختبارات وظائف الكبد، يمكن أن تؤخذ الجرعة اليومية الكلية مرة واحدة يوميًا في المساء.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p dir="RTL">وزن الجسم<br />(كيلوجرام)</p></td><td colspan="4" style="vertical-align:top"><p dir="RTL">كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL">أول ثلاثة أشهر</p></td><td style="vertical-align:top"><p dir="RTL">في وقت لاحق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">في الصباح</p></td><td style="vertical-align:top"><p dir="RTL">في الظهيرة</p></td><td style="vertical-align:top"><p dir="RTL">في المساء</p></td><td style="vertical-align:top"><p dir="RTL">في المساء</p><p dir="RTL">(مرة واحدة يوميًا)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">47 &ndash; 62</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">3</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">63 &ndash; 78</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">4</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">79 &ndash; 93</p></td><td style="vertical-align:top"><p dir="RTL">1</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">5</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">94 &ndash; 109</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">6</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أكثر من 110</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">2</p></td><td style="vertical-align:top"><p dir="RTL">3</p></td><td style="vertical-align:top"><p dir="RTL">7</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوافر معلق Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام لكل 5 مليلتر إذا كان وزنك أقل من 47 كجم أو لا يمكنك ابتلاع كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيفية تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام</p><p dir="RTL">قم بابتلاع الكبسولات كاملة دون مضغها مع بعض السوائل،وقم بتناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام بصفة منتظمة.</p><p dir="RTL"><em><u>&nbsp;</u></em></p><p dir="RTL">مدة العلاج</p><p dir="RTL">لا يمكن أن يستمر تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام إلى أجل غير مسمى في حالات تليف الكبد الصفراوي الأولي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ملاحظة:</p><p dir="RTL">في المرضى الذين يعانون من تليف الكبد الصفراوي الأولي، قد تزداد أعراض بعض الأمراض، مثل الحكة، سوءًا في بداية العلاج،ويحدث هذا فقط في حالات نادرة،في هذه الحالة، يمكن أن يستمر العلاج مع جرعة يومية أقل من Ursofalk<sup>&reg;</sup> (يرسوفالك)250 مليجرام،ثم يقوم الطبيب بزيادة الجرعة اليومية تدريجيًا، أسبوعا بعد أسبوع، حتى الوصول إلى الجرعة المطلوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال العقار مع الأطفال لعلاج مرض الكبد المرتبط بالتليف الكيسي </strong><strong>(</strong><strong>من </strong><strong>6 </strong><strong>سنوات حتى أقل من </strong><strong>18</strong><strong>سنة</strong><strong>)</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعة اليومية الموصى بها هي 20 مليجرام لكل كيلوجرام من وزن الجسم، مقسمة على جرعتين &ndash; 3 جرعات،قد يرغب طبيبك في زيادة الجرعة إلى 30 مليجرام لكل كيلوجرام من وزن الجسم يوميًا إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p dir="RTL">وزن الجسم</p><p dir="RTL">وزن الجسم [كيلوجرام]</p></td><td rowspan="2"><p dir="RTL">الجرعة اليومية</p><p dir="RTL">(مليجرام/كيلوجرام من وزن الجسم)</p></td><td colspan="3"><p dir="RTL">&nbsp;</p><p dir="RTL">كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام الصلبة</p></td></tr><tr><td><p dir="RTL">في الصباح</p></td><td><p dir="RTL">في الظهيرة</p></td><td><p dir="RTL">في المساء</p></td></tr><tr><td><p dir="RTL">20 &ndash; 29</p></td><td><p dir="RTL">17-25</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">&nbsp;--</p></td><td><p dir="RTL">1</p></td></tr><tr><td><p dir="RTL">30 &ndash; 39</p></td><td><p dir="RTL">19-25</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">1</p></td></tr><tr><td><p dir="RTL">40 &ndash; 49</p></td><td><p dir="RTL">20-25</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">2</p></td></tr><tr><td><p dir="RTL">50 &ndash; 59</p></td><td><p dir="RTL">21-25</p></td><td><p dir="RTL">1</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">2</p></td></tr><tr><td><p dir="RTL">60 &ndash; 69</p></td><td><p dir="RTL">22-25</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">2</p></td></tr><tr><td><p dir="RTL">70 &ndash; 79</p></td><td><p dir="RTL">22-25</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">3</p></td></tr><tr><td><p dir="RTL">80 &ndash; 89</p></td><td><p dir="RTL">22-25</p></td><td><p dir="RTL">2</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">3</p></td></tr><tr><td><p dir="RTL">90 &ndash; 99</p></td><td><p dir="RTL">23-25</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">3</p></td></tr><tr><td><p dir="RTL">100 &ndash; 109</p></td><td><p dir="RTL">23-25</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">4</p></td></tr><tr><td><p dir="RTL">&gt;110</p></td><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">3</p></td><td><p dir="RTL">4</p></td><td><p dir="RTL">4</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كنت تشعر بأن تأثير كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام قوية جدًا أو ضعيفة جدًا.</p><p dir="RTL">&nbsp;</p><p>في حال تناولك كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام أكثر من الجرعة الموصى بها:</p><p dir="RTL">قد يحدث إسهال نتيجة زيادة الجرعة،برجاء إبلاغ الطبيب على الفور إذا كنت تعاني من إسهال مستمر،إذا كنت تعاني من الإسهال، تأكد من شرب ما يكفي من السوائل لاستعادة توازن السوائل والإلكتروليت.</p><p dir="RTL">&nbsp;</p><p>في حال نسيان تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام:</p><p dir="RTL">لا تتناول عدد أكبر من الكبسولات في المرة التالية، ولكن استمر في العلاج من خلال الجرعة الموصوفة.</p><p dir="RTL">&nbsp;</p><p>في حال التوقف عن تناول كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام:</p><p dir="RTL">احرص على التحدث مع طبيبك قبل الانقطاع عن تناول كبسولاتUrsofalk<sup>&reg;</sup> (يرسوفالك) 250 أو التوقف عن العلاج قبل الموعد المحدد</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر الطبيب المعالج أو الصيدلي في حال وجود أي أسئلة أخرى حول استعمال هذا العقار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد ينتج عن تناول هذا العقار بعض الآثار الجانبية، وإن لم يكن ذلك بوجه عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (تصيب أقل من شخص بين كل 10 أشخاص وأكثر من شخص بين كل 100 شخص ممن تناولوا العلاج):</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>براز طري أو رخو أو إسهال</p><p dir="RTL">الآثار الجانبية النادرة للغاية (تصيب أقل من شخص بين كل 10000 ممن تناولوا العلاج):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء علاج تليف الكبد الصفراوي الأولي: ألم شديد في الجانب العلوي الأيمن من البطن وتدهور شديد لتليف الكبد (انهيار المُعاوضة) الذي يرتد جزئيا بعد توقف العلاج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكلس حصوات المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح القراص (الأرتكاريا)</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الآثار الجانبية</p><p dir="RTL">تحدث إلى الطبيب أو الصيدلي في حال حدوث أي من الأعراض الجانبية،ويشمل هذا أي أعراض جانبية محتملة غير مدوّنة في هذه النشرة،</p><p dir="RTL">يمكن أن يساعد ذلك في توفير مزيد من المعلومات حول مدى سلامة هذا العقار من خلال الإبلاغ عن الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا العقار بعيدًا عن متناول الأطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُحظر استخدام هذا العقار بعد انتهاء تاريخ الصلاحية المدون على العبوة،يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في درجة حرارة أقل من 25 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتوى كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك)250 مليجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعالة هي حمض أورسوديوكسيكوليك،تحتوي الكبسولة الواحدة على 250 مليجرام من حمض أورسوديوكسيكوليك.</p><p dir="RTL">المكونات الأخرى هي</p><p>جيلاتين، سيليكا غروية لامائية، ستيرات المغنيسيوم، نشا الذرة، دوديسيل كبريتات صوديوم، ثاني أكسيد التيتانيوم<strong>،</strong>مياه نقية<strong>.</strong><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك)250 مليجرام بيضاء وغير شفافة، حيث تحتوي على مسحوق أبيض أو حبيبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوافر كبسولات Ursofalk<sup>&reg;</sup> (يرسوفالك) 250 مليجرام في عبوات من 50 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل تصريح التسويق:</p><p>DR. FALK PHARMA GmbH</p><p>Leinenweberstr. 5</p><p>79108 Freiburg</p><p>Germany</p><p dir="RTL">هاتف: (0761) 1514 0</p><p dir="RTL">فاكس: (0761) 1514 321</p><p dir="RTL">بريد إلكتروني: zentrale@drfalkpharma.de</p><p dir="RTL">&nbsp;</p><p>لمعرفة أي معلومات عن هذا المنتج الدوائي، يرجى التواصل مع الوكيل المحلي لحامل تصريح التسويق:</p><p>&nbsp;</p><p>مؤسسات سقالة</p><p>مكتب 511، الدور الخامس، مبنى العقارية الثانية،</p><p>شارع العليا العام، الرياض 11533، المملكة العربية السعودية.</p><p>صندوق بريد 50622</p><p dir="RTL">تليفون: 4191471 11 966+</p><p dir="RTL">فاكس: 4191652 11 966+</p><p>info.reg@cigalah.com.saإيميل:</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>المملكة العربية السعودية</em>:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-20511--966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات 2038222-11-966+&nbsp; تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>دول الخليج العربي الأخرى</em>:</p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.</p><p>&nbsp;</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL">بيانات النشرة الداخلية معتمدة من قبل الهيئة العامة للغذاء والدواء</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ آخر مراجعة لهذه النشرة: أغسطس 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ursofalk 250mg capsules
	Ursodeoxycholic acid

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 hard capsule of Ursofalk 250mg capsules contains 250 mg ursodeoxycholic acid (UDCA) as the active substance.

	For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules

	Appearance: white, opaque hard gelatin capsules, capsule size 0, which contain a white compressed powder or granulate.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the dissolution of cholesterol gallstones in the gall bladder. The gallstones must not show as shadows on X-ray images and should not exceed 15 mm in diameter. Gall bladder function must not be significantly impaired, despite the gallstones.<br /><br />For the treatment of bile reflux gastritis.<br /><br />For the treatment of primary biliary cirrhosis (PBC) in patients without decompensated hepatic cirrhosis.</p><p>&nbsp;</p><p><u>Paediatric population:</u></p><p>For the treatment of hepatobiliary disorder associated with cystic fibrosis in children aged 6 years to less than 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no age restrictions on the use of Ursofalk<sup>&Ograve;</sup> 250mg capsules. For patients weighing less than 47 kg or patients who are unable to swallow Ursofalk<sup>&Ograve;</sup> 250mg capsules, Ursofalk<sup>&Ograve;</sup> 250mg/5ml suspension is available.</p><p><u>&nbsp;</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following daily dose is recommended for the various indications:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>For dissolution of cholesterol gallstones </u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Approx. 10 mg of UDCA per kg of body weight, equivalent to:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; up to 60 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 hard capsules</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61 - 80 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 hard capsules</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 81 - 100 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hard capsules</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; over&nbsp;&nbsp;&nbsp; 100 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 hard capsules</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The hard capsules should be swallowed whole with some liquid in the evening at bedtime.</p><p>They must be taken regularly.</p><p><u>&nbsp;</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The time required for the dissolution of gallstones is generally 6-24 months. If there is no reduction in the size of the gallstones after 12 months, the therapy should not be continued.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The success of the treatment should be checked by means of ultrasound or X-ray examination every 6 months. At the follow-up examinations, a check should be made to see whether calcification of the stones has occurred in the meantime. Should this be the case, the treatment must be ended.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>For the treatment of bile reflux gastritis</u></p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 hard capsule of Ursofalk<sup>&Ograve;</sup> 250mg capsules should be swallowed whole with some liquid once daily in the evening before bedtime.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of bile reflux gastritis Ursofalk<sup>&Ograve;</sup> 250mg capsules should normally be taken for 10 &ndash; 14 days. In general the duration of use depends on the course of the disease. The treating physician will decide on the duration of use in the individual case.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>For the treatment of PBC</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The daily dose depends on body weight, and ranges from 3 to 7 hard capsules (14 &plusmn; 2 mg UDCA per kg of body weight).</p><p>For the first 3 months of treatment, Ursofalk<sup>&Ograve;</sup> 250mg capsules should be taken in divided doses throughout the day. When the liver function parameters improve, the daily dose may be taken once daily in the evening.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:449px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Body weight (kg)</p></td><td colspan="4" style="vertical-align:top"><p>Ursofalk<sup>&Ograve;</sup> 250mg capsules</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>first 3 months</strong></p></td><td style="vertical-align:top"><p><strong>subsequently</strong></p></td></tr><tr><td style="vertical-align:top"><p>morning</p></td><td style="vertical-align:top"><p>midday</p></td><td style="vertical-align:top"><p>evening</p></td><td style="vertical-align:top"><p>evening</p><p>(1 x daily)</p></td></tr><tr><td style="vertical-align:top"><p>47 &ndash; 62</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>63 &ndash; 78</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>79 &ndash; 93</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>94 &ndash; 109</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Over 110</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>7</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>The hard capsules should be swallowed whole with some liquid. Ursofalk<sup>&Ograve;</sup> 250mg capsules must be taken regularly.</p><p>&nbsp;</p><p>The use of Ursofalk<sup>&Ograve;</sup> 250mg capsules in PBC may be continued indefinitely.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with PBC, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g. the itching may increase. In this event, therapy should first be continued with one Ursofalk<sup>&Ograve;</sup> 250mg capsule daily, and the dose then gradually increased (weekly increase of the daily dose by one hard capsule) until the dose indicated in the respective dosage regimen is reached again.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p><u>Children with cystic fibrosis aged 6 years to less than 18 years:</u></p><p><u>&nbsp;</u></p><p>20 mg/kg/day in 2-3 divided doses, with a further increase to 30 mg/kg/day if necessary</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Body weight</strong></p><p><strong>BW (kg)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Daily dose</strong></p><p><strong>(mg/kg BW)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ursofalk 250mg hard capsules</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Morning</strong></p></td><td style="vertical-align:top"><p><strong>Midday</strong></p></td><td style="vertical-align:top"><p><strong>Evening</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>20 &ndash; 29</strong></p></td><td style="vertical-align:top"><p>17-25</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&nbsp;--</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>30 &ndash; 39</strong></p></td><td style="vertical-align:top"><p>19-25</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>40 &ndash; 49</strong></p></td><td style="vertical-align:top"><p>20-25</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>50 &ndash; 59</strong></p></td><td style="vertical-align:top"><p>21-25</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>60 &ndash; 69</strong></p></td><td style="vertical-align:top"><p>22-25</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>70 &ndash; 79</strong></p></td><td style="vertical-align:top"><p>22-25</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>80 &ndash; 89</strong></p></td><td style="vertical-align:top"><p>22-25</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>90 &ndash; 99</strong></p></td><td style="vertical-align:top"><p>23-25</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>100 &ndash; 109</strong></p></td><td style="vertical-align:top"><p>23-25</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;110</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ursofalk 250mg capsules should not be used in patients with:

	acute inflammation of the gall bladder or biliary tract
	occlusion of the biliary tract (occlusion of the common bile duct or a cystic duct)
	frequent episodes of biliary colic
	radio-opaque calcified gallstones
	impaired contractility of the gall bladder
	hypersensitivity to bile acids or any of the excipients listed in section 6.1.

Paediatric population
	Unsuccessful portoenterostomy or without recovery of good bile flow in children with biliary atresia

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ursofalk<sup>&Ograve;</sup> 250mg capsules should be taken under medical supervision.</p><p><strong><u>&nbsp;</u></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During the first 3 months of treatment, the liver function parameters AST (SGOT), ALT (SGPT) and g-GT should be monitored by the physician every 4 weeks, thereafter every 3 months. Apart from allowing for identification of responders and non-responders in patients being treated for PBC, this monitoring would also enable early detection of potential hepatic deterioration, particularly in patients with advanced stage PBC.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>When used for the dissolution of cholesterol gallstones</u>:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In order to assess therapeutic progress and for timely detection of any calcification of the gallstones, depending on stone size, the gall bladder should be visualised (oral cholecystography) with overview and occlusion views in standing and supine positions (ultrasound control) 6-10 months after the beginning of treatment.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the gall bladder cannot be visualised on X-ray images, or in cases of calcified gallstones, impaired contractility of the gall bladder or frequent episodes of biliary colic, Ursofalk<sup>&Ograve;</sup> 250mg capsules should not be used.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Female patients taking Ursofalk<sup>&Ograve;</sup> 250mg capsules for dissolution of gallstones should use an effective non-hormonal method of contraception, since hormonal contraceptives may increase biliary lithiasis (see section 4.5 and 4.6).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>When used for treatment of advanced stage of PBC</u>:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In very rare cases decompensation of hepatic cirrhosis has been observed, which partially regressed after the treatment was discontinued.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with PBC, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g. the itching may increase. In this case the dose of Ursofalk<sup>&Ograve;</sup> 250mg capsules should be reduced to one Ursofalk<sup>&Ograve;</sup> 250mg capsule daily and then gradually increased again as described in section 4.2.</p><p>&nbsp;</p><p>If diarrhoea occurs, the dose must be reduced and in cases of persistent diarrhoea, the therapy should be discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ursofalk<sup>&Ograve;</sup> 250mg capsules should not be administered concomitantly with colestyramine, colestipol or antacids containing aluminium hydroxide and/or smectite (aluminium oxide), because these preparations bind UDCA in the intestine and thereby inhibit its absorption and efficacy. Should the use of a preparation containing one of these substances be necessary, it must be taken at least 2 hours before or after Ursofalk<sup>&Ograve;</sup> 250mg capsules.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ursofalk<sup>&Ograve;</sup> 250mg capsules can affect the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by the physician and the ciclosporin dose adjusted if necessary.</p><p>&nbsp;</p><p>In isolated cases Ursofalk<sup>&Ograve;</sup> 250mg capsules can reduce the absorption of ciprofloxacin.</p><p>&nbsp;</p><p>In a clinical study in healthy volunteers concomitant use of UDCA (500 mg/day) and rosuvastatin (20 mg/day) resulted in slightly elevated plasma levels of rosuvastatin. The clinical relevance of this interaction also with regard to other statins is unknown.</p><p>&nbsp;</p><p>UDCA has been shown to reduce the plasma peak concentrations (C<sub>max</sub>) and the area under the curve (AUC) of the calcium antagonist nitrendipine in healthy volunteers. Close monitoring of the outcome of concurrent use of nitrendipine and UDCA is recommended. An increase of the dose of nitrendipine may be necessary.</p><p>An interaction with a reduction of the therapeutic effect of dapsone was also reported.</p><p>&nbsp;</p><p>These observations, together with in-vitro findings could indicate a potential for UDCA to induce cytochrome P450 3A enzymes. Induction has, however, not been observed in a well-designed interaction study with budesonide, which is a known cytochrome P450 3A substrate.</p><p>&nbsp;</p><p>Oestrogenic hormones and blood cholesterol lowering agents, such as clofibrate, increase hepatic cholesterol secretion and may therefore encourage biliary lithiasis, which is a counter-effect to UDCA used for dissolution of gallstones.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies did not show an influence of UDCA on fertility (see section 5.3). Human data on fertility effects following treatment with UDCA are not available.</p><p>&nbsp;</p><p>There are no or limited amounts of data from the use of UDCA in pregnant women. Studies in animals have shown reproductive toxicity during the early phase of gestation (see section 5.3). Ursofalk<sup>&Ograve;</sup> 250mg capsules must not be used during pregnancy unless clearly necessary. Women of childbearing potential should be treated only if they are using reliable contraception.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-hormonal or low-oestrogen oral contraceptive measures are recommended. However, in patients taking Ursofalk<sup>&Ograve;</sup> 250mg capsules for dissolution of gallstones, effective non-hormonal contraception should be used, since hormonal oral contraceptives may increase biliary lithiasis. The possibility of a pregnancy must be excluded before beginning treatment.</p><p>&nbsp;</p><p>According to few documented cases of breastfeeding women milk levels of UDCA are very low and probably no adverse reactions are to be expected in breastfed infants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ursofalk<sup>&reg; </sup>250mg capsules have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The evaluation of undesirable effects is based on the following frequency data:</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (&sup3; 1/10)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (&sup3; 1/100 to &lt; 1/10)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (&sup3; 1/1.000 to &lt; 1/100)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (&sup3; 1/10.000 to &lt; 1/1.000)</p><p>Very rare / Not known (&lt;1/10,000 / cannot be estimated from available data)</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Gastrointestinal disorders:</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In clinical trials, reports of soft stools or diarrhoea during UDCA therapy were common.<br />Very rarely, severe right upper abdominal pain has occurred during the treatment of PBC.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hepatobiliary disorders:</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment with UDCA, calcification of gallstones can occur in very rare cases.<br />During therapy of the advanced stages of PBC, in very rare cases decompensation of hepatic cirrhosis has been observed, which partially regressed after the treatment was discontinued.</p><p><em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Skin and subcutaneous tissue disorders:</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rarely, urticaria can occur.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diarrhoea may occur in cases of overdose. In general, other symptoms of overdose are unlikely because the absorption of UDCA decreases with increasing dose and therefore more is excreted with the faeces.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No specific counter-measures are necessary and the consequences of diarrhoea should be treated symptomatically with restoration of fluid and electrolyte balance.</p><p>&nbsp;</p><p>Additional information on special populations:</p><p>Long-term, high-dose UDCA therapy (28-30 mg/kg/day) in patients with primary sclerosing cholangitis (off-label use) was associated with higher rates of serious adverse events.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ursodeoxycholic acid and liver therapy, lipotropics,<br />&nbsp;</p><p>ATC code: A05AA02 and A05B</p><p><strong><u>&nbsp;</u></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small amounts of UDCA are found in human bile.<br /><br />After oral administration, UDCA reduces cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and decreasing cholesterol secretion into the bile. Presumably as a result of dispersion of the cholesterol and formation of liquid crystals, a gradual dissolution of cholesterol gallstones occurs.<br />&nbsp;</p><p>According to current knowledge, the effect of UDCA in hepatic and cholestatic diseases is thought to be due to a relative exchange of lipophilic, detergent-like, toxic bile acids for the hydrophilic, cytoprotective, non-toxic UDCA, to an improvement in the secretory capacity of the hepatocytes, and to immune-regulatory processes.</p><p>&nbsp;</p><p><u>Paediatric population:</u></p><p><u>&nbsp;</u></p><p><u>Cystic fibrosis</u></p><p>&nbsp;</p><p>From clinical reports long-term experience up to 10 years and more is available with UDCA treatment in paediatric patients suffering from cystic fibrosis-associated hepatobiliary disease (CFAHD). There is evidence that treatment with UDCA can decrease bile duct proliferation, halt progression of histological damage and even reverse hepatobiliary changes if given at early stage of CFAHD. Treatment with UDCA should be started as soon as the diagnosis of CFAHD is made in order to optimise treatment effectiveness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orally administered UDCA is rapidly absorbed in the jejunum and upper ileum through passive transport and in the terminal ileum through active transport. The rate of absorption is generally 60-80%. After absorption, UDCA undergoes almost complete hepatic conjugation with the amino acids glycine and taurine and is then excreted with the bile. First-pass clearance through the liver is up to 60%.</p><p><br />Depending on the daily dose and underlying disorder or condition of the liver, the more hydrophilic UDCA accumulates in the bile. At the same time, a relative decrease in other, more lipophilic, bile acids is observed.</p><p>Under the influence of intestinal bacteria, there is partial degradation to 7-keto-lithocholic acid and lithocholic acid. Lithocholic acid is hepatotoxic and causes liver parenchyma damage in a number of animal species. In humans, only very small amounts are absorbed, which are sulphated in the liver and thus detoxified, before being excreted in the bile and ultimately in the faeces.<br /><br />The biological half-life of UDCA is 3.5-5.8 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a) Acute toxicity</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute toxicity studies in animals have not revealed any toxic damage.</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; b) Chronic toxicity</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subchronic toxicity studies in monkeys showed hepatotoxic effects in the groups given high doses, including functional changes (e.g. liver enzyme changes) and morphological changes such as bile duct proliferation, portal inflammatory foci and hepatocellular necrosis. These toxic effects are most likely attributable to lithocholic acid, a metabolite of UDCA, which in monkeys &ndash; unlike humans &ndash; is not detoxified. Clinical experience confirms that the described hepatotoxic effects are of no apparent relevance in humans.</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; c) Carcinogenic and mutagenic potential</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term studies in mice and rats revealed no evidence of UDCA having carcinogenic potential.<br />In vitro and in vivo genotoxicity tests with UDCA were negative.</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; d) Toxicity to reproduction</p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In studies in rats, tail aplasia occurred after a dose of 2000 mg of UDCA per kg of body weight. In rabbits, no teratogenic effects were found, although there were embryotoxic effects (from a dose of 100 mg per kg of body weight). UDCA had no effect on fertility in rats and did not affect peri-/post-natal development of the offspring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>List of excipients</strong></p><p><strong>&nbsp;</strong></p><p>1.&nbsp;&nbsp;&nbsp; Gelatin</p><p>2.&nbsp;&nbsp;&nbsp; Silica, colloidal anhydrous</p><p>3.&nbsp;&nbsp;&nbsp; Magnesium stearate (Ph.Eur.) [herbal]</p><p>4.&nbsp;&nbsp;&nbsp; Maize starch</p><p>5.&nbsp;&nbsp;&nbsp; Sodium dodecyl sulphate</p><p>6.&nbsp;&nbsp;&nbsp; Titanium dioxide (E 171)</p><p>7.&nbsp;&nbsp;&nbsp; Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent, colourless PVC foil, welded with hot seal lacquer to aluminium foil</p><p>&nbsp;</p><p><u>Pack sizes:</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Original packs with 50 hard capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dr. Falk Pharma GmbH
	Leinenweberstr. 5
	79108 Freiburg
	Germany
	Tel.: +49 (0)761/1514-0
		Fax: +49 (0)761/1514-321
		E-mail: zentrale@drfalkpharma.de

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>